

Roles of Smad7 in Chondrocyte Differentiation




FIGURE 7. Overexpression of Smad7 inhibits BMP-induced cartilaginous nodule formation and down-regulates p38 MAPK pathways in micromass cultures. A, mesenchymal cells from the first line of *Smad7^{trn1}*, the other line of *Smad7^{trn1}*, and *Col11a2-Smad6* transgenic limb buds were cultured in micromass in the presence of various concentrations of rhBMP2 for 4 days. Mesenchymal cells prepared from the first line of *Smad7^{trn1}* and the other line of *Smad7^{trn1}* showed decreased formation of cartilaginous nodules. Error bars indicate means \pm S.D. ($n = 3$). **, $p < 0.01$ between cultures of Smad7 or Smad6 transgenic mesenchymal cells and cultures of wild-type mesenchymal cells as determined by Student's *t* test. B, shown are the results from marker gene expression analysis of micromass cultures of the first line of *Smad7^{trn1}* and *Col11a2-Smad6* transgenic mesenchymal cells in the presence of rhBMP2 for 4 days by real-time RT-PCR. Expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase expression. The wild-type expression level was set as 1. Error bars indicate means \pm S.D. ($n = 3$). *, $p < 0.05$; **, $p < 0.01$ between control and transgenic mesenchymal cells as determined by Student's *t* test. C, mesenchymal cells from wild-type limb buds were infected with Smad7 (second row) or Smad6 (third row) adenoviral (Ad) vectors. Cartilaginous nodule formation was down-regulated by Smad7 (but not Smad6) adenoviral infection. **, $p < 0.01$ between control cultures and cultures infected with Smad7 or Smad6 adenoviral vectors as determined by Student's *t* test. D, shown are the results from gene expression analysis of micromass cultures of mesenchymal cells infected with Smad6 or Smad7 adenoviral vectors in the presence of rhBMP2 for 4 days by real-time RT-PCR. Expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase expression. The wild-type expression level was set as 1. Error bars indicate means \pm S.D. ($n = 3$). *, $p < 0.05$ between control cultures and cultures infected with Smad7 or Smad6 adenoviral vectors as determined by Student's *t* test. Scale bars = 1 mm. E, mesenchymal cells from wild-type mice in micromass cultures were infected with Smad7 or Smad6 adenoviral vectors, lysed, and subjected to immunoblot analysis for phosphorylation of Smad1/5/8, p38, ATF2, and Smad2 and for expression of Smad7 and Smad6.

These results collectively suggest that controlled expression of Smad7 is crucial for normal cartilage development and homeostasis to sustain anabolic BMP/TGF- β signals.

Smad7 in Prechondrogenic Cells Inhibits Chondrocyte Differentiation and Down-Regulates BMP-activated p38 MAPK Pathways— Overexpression of Smad7 in condensing mesenchymal cells inhibited condensation and subsequent cartilage formation in *Smad7^{trn1}* mice. Because mouse limb cartilage develops almost normally without TGF- β receptor type II (22), we speculated that Smad7 overexpression inhibited cartilage formation by inhibiting BMP signals in *Smad7^{trn1}* mice. Cartilage does not form in mice that lack BMP signals in chondrocytes (11, 12). However, cartilage forms in mice lacking Smad4 (20) and in mice overexpressing Smad6 (21) in chondrocytes, suggesting that non-Smad pathways may mediate BMP-induced cartilage formation. During chondrogenesis of chick mesenchymal cells, p38 phosphorylation is increased. The inhibitor of p38 MAPK pathways blocks chondrogenesis (34). BMP signals increase Sox9 expression in mesenchymal cells (31). Sox9 is likely a downstream target of the p38 MAPK pathway in chondrocytes (40). Sox9 promotes cartilage formation (41). Based on these findings, it is reasonable to assume that MAPK pathways mediate BMP-induced cartilage formation through increased expression of Sox9. Sox9 expression was decreased in condensing mesenchyme in *Smad7^{trn1}* mice. Together with these findings, the present result that Smad7 overexpression down-regulated the phosphorylation of p38 and ATF2 suggested that Smad7 inhibits cartilage formation, possibly by down-regulating BMP-activated p38 MAPK pathways. Accordingly, Smad7 has been reported to inhibit activation of BMP-activated p38 MAPK pathways in neuronal cells (5).

A high level of overexpression of Smad6 or Smad7 could nonspecifically affect signaling pathways (2). In the present study, the expression levels of the *Smad7* transgene were as much as those of endogenous Smad7 in the tissues surrounding cartilage as examined by *in situ* hybridization analysis (Fig. 6B). Although we con-




FIGURE 8. Smad7 inhibits p38 MAPK pathways upstream of MKK3 in ATDC5 cells. A, undifferentiated ATDC5 cells were infected with LacZ, Smad7, or Smad6 adenoviral (*Ad*) vectors; lysed; and subjected to immunoblot analysis for phosphorylation of Smad1/5/8, p38, and ATF2 and for expression of Smad7 and Smad6. B, ATDC5 cells were infected with constitutively active (*ca*) MKK3, LacZ, Smad7, or Smad6 adenoviral vectors; lysed; and subjected to immunoblot analysis for phosphorylation of p38 and ATF2 and for expression of Smad7 and Smad6.

cluded that Smad7 overexpression inhibits cartilage formation, at least in part, by inhibiting BMP-activated MAPK pathways, we do not deny the notion that canonical Smad pathways also induce cartilage formation and chondrocyte proliferation because Smad7 and Smad6 overexpression partially suppressed the phosphorylation of Smad1/5/8, p38, and ATF2 in the present culture study. Further suppression of the phosphorylation of Smad1/5/8 might interfere with cartilage formation. In addition, it is also possible that Smad7 affects TGF- β signals in cartilage, leading to inhibition of cartilage formation in *Smad7^{Prx1}* mice.

Smad7 in Round Chondrocytes Decreases the Chondrocyte Proliferation Rate—The decreased expression of *Hist2* in *Smad7^{11Enh}* mice proved that Smad7 overexpression in proliferative chondrocytes inhibits chondrocyte proliferation because *Smad7* transgene expression begins at the stage of round proliferative chondrocytes, allowing a normal transition from condensed mesenchyme to round chondrocytes in *Smad7^{11Enh}* mice. It was reported that the chondrocyte proliferation rate is decreased in *Bmpr1b^{+/-};Bmpr1a^{CKO};Col2a1-*

Cre mice (42). In contrast, the chondrocyte proliferation rate is normal in mice lacking TGF- β receptor type II in chondrocytes (22). The chondrocyte proliferation rate is normal in transgenic mice overexpressing Smad6 in chondrocytes, although the phosphorylation of Smad1/5/8 is down-regulated (21). These findings suggest that chondrocyte proliferation is controlled by BMP signals and Smad7, but not by TGF- β signals or Smad6. Because the activation of the p38 MAPK pathways decreases the chondrocyte proliferation rate (40), another pathway may mediate BMP-induced chondrocyte proliferation. This other pathway remains to be elucidated.

Smad7 in Flat Chondrocytes Delays Maturation toward Hypertrophy—*Smad7^{11Prom}* mice showed delayed chondrocyte hypertrophy. We previously reported that Smad6 overexpression inhibits BMP-induced chondrocyte hypertrophy associated with the inhibition of Smad1/5/8 phosphorylation (21). BMP signals generally stimulate chondrocyte hypertrophy (10, 43). However, the chondrocyte-specific deletion of *Tgfb2* does not affect chondrocyte hypertrophy (22). p38 MAPK activity is required for chondrocyte hypertrophy (44). Combined with these findings, the present results raise possibilities that Smad7 overexpression may delay hypertrophy of flat chondrocytes by inhibiting the activation of Smad1/5/8 and p38 MAPK pathways. It remains to be determined whether Smad7 affects p38 MAPK pathways in differentiated chondrocytes.

In summary, we established a Smad7 conditional transgenic mouse system and found that Smad7 overexpression exerts functions at multiple stages of chondrocyte differentiation. Our results suggest that Smad7 inhibits cartilage formation, possibly by down-regulating BMP-activated p38 MAPK pathways. Smad7 is overexpressed in various pathological states, including cancers and inflammation. In joint diseases such as osteoarthritis, cartilage expresses Smad7 (15). In cultured articular chondrocytes, stimulation with the inflammatory cytokine interleukin-1 β up-regulates Smad7 (14, 15). Although we should be cautious in interpreting our data, the findings of this Smad7 overexpression study should contribute to an understanding of the mechanism that interferes with the recovery of damaged cartilage despite treatment in the course of joint diseases.

Acknowledgments—We thank Dr. Jun-ichi Miyazaki for helpful discussion and CAG-CAT^{flx}-lacZ transgenic mice and Dr. Takeshi Imamura for helpful discussion and Smad6 and Smad7 adenoviral vectors. We thank Dr. Malcolm Logan for Prx1-Cre transgenic mice and Dr. Riko Nishimura for constitutively active MKK3 adenoviral vectors. We are indebted to Kunihiko Hiramatsu, Mina Okamoto, and Mari Shinkawa for technical support.

REFERENCES

- Miyazono, K., Kusanagi, K., and Inoue, H. (2001) *J. Cell. Physiol.* **187**, 265–276
- Massague, J., Seoane, J., and Wotton, D. (2005) *Genes Dev.* **19**, 2783–2810
- Derynck, R., and Zhang, Y. E. (2003) *Nature* **425**, 577–584
- Goto, K., Kamiya, Y., Imamura, T., Miyazono, K., and Miyazawa, K. (2007) *J. Biol. Chem.* **282**, 20603–20611
- Yanagisawa, M., Nakashima, K., Takeda, K., Ochiai, W., Takizawa, T., Ueno, M., Takizawa, M., Shibuya, H., and Taga, T. (2001) *Genes Cells* **6**, 1091–1099

Roles of Smad7 in Chondrocyte Differentiation

- Luukko, K., Ylikorkala, A., and Makela, T. P. (2001) *Mech. Dev.* **101**, 209–212
- Li, R., Rosendahl, A., Brodin, G., Cheng, A. M., Ahgren, A., Sundquist, C., Kulkarni, S., Pawson, T., Heldin, C. H., and Heuchel, R. L. (2006) *J. Immunol.* **176**, 6777–6784
- Kronenberg, H. M. (2006) *Ann. N. Y. Acad. Sci.* **1068**, 1–13
- Olsen, B. R., Reginato, A. M., and Wang, W. (2000) *Annu. Rev. Cell Dev. Biol.* **16**, 191–220
- Kobayashi, T., Lyons, K. M., McMahon, A. P., and Kronenberg, H. M. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 18023–18027
- Yoon, B. S., Ovchinnikov, D. A., Yoshii, I., Mishina, Y., Behringer, R. R., and Lyons, K. M. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5062–5067
- Tsumaki, N., Nakase, T., Miyaji, T., Kakiuchi, M., Kimura, T., Ochi, T., and Yoshikawa, H. (2002) *J. Bone Miner. Res.* **17**, 898–906
- Sakou, T., Onishi, T., Yamamoto, T., Nagamine, T., Sampath, T., and Ten Dijke, P. (1999) *J. Bone Miner. Res.* **14**, 1145–1152
- Bauge, C., Legendre, F., Leclercq, S., Ellissalde, J. M., Pujol, J. P., Galera, P., and Boumediene, K. (2007) *Arthritis Rheum.* **56**, 3020–3032
- Kaiser, M., Haag, J., Soder, S., Bau, B., and Aigner, T. (2004) *Arthritis Rheum.* **50**, 3535–3540
- Ito, Y., Bringas, P., Jr., Mogharei, A., Zhao, J., Deng, C., and Chai, Y. (2002) *Dev. Dyn.* **224**, 69–78
- Scharstuhl, A., Diepens, R., Lensen, J., Vitters, E., van Beuningen, H., van der Kraan, P., and van den Berg, W. (2003) *Osteoarthritis Cartilage* **11**, 773–782
- Fujii, M., Takeda, K., Imamura, T., Aoki, H., Sampath, T. K., Enomoto, S., Kawabata, M., Kato, M., Ichijo, H., and Miyazono, K. (1999) *Mol. Cell Biol.* **19**, 3801–3813
- Valcourt, U., Gouttenoire, J., Moustakas, A., Herbage, D., and Mallein-Gerin, F. (2002) *J. Biol. Chem.* **277**, 33545–33558
- Zhang, J., Tan, X., Li, W., Wang, Y., Wang, J., Cheng, X., and Yang, X. (2005) *Dev. Biol.* **284**, 311–322
- Horiki, M., Imamura, T., Okamoto, M., Hayashi, M., Murai, J., Myoui, A., Ochi, T., Miyazono, K., Yoshikawa, H., and Tsumaki, N. (2004) *J. Cell Biol.* **165**, 433–445
- Baffi, M. O., Slattery, E., Sohn, P., Moses, H. L., Chytil, A., and Serra, R. (2004) *Dev. Biol.* **276**, 124–142
- Tsumaki, N., Kimura, T., Matsui, Y., Nakata, K., and Ochi, T. (1996) *J. Cell Biol.* **134**, 1573–1582
- Logan, M., Martin, J. F., Nagy, A., Lobe, C., Olson, E. N., and Tabin, C. J. (2002) *Genesis* **33**, 77–80
- Peters, P. W. J. (1977) in *Methods in Prenatal Toxicology* (Neuberg, H. J. M. D., and Kwasigroch, T. E., eds) pp. 153–154. Georg Thieme Verlag, Stuttgart, Germany
- Muskhelishvili, L., Latendresse, J. R., Kodell, R. L., and Henderson, E. B. (2003) *J. Histochem. Cytochem.* **51**, 1681–1688
- Fujimaki, R., Toyama, Y., Hozumi, N., and Tezuka, K. (2006) *J. Bone Miner. Metab.* **24**, 191–198
- Shukunami, C., Shigeno, C., Atsumi, T., Ishizeki, K., Suzuki, F., and Hiraki, Y. (1996) *J. Cell Biol.* **133**, 457–468
- Sakai, K., and Miyazaki, J. (1997) *Biochem. Biophys. Res. Commun.* **237**, 318–324
- Fujimaki, R., Hayashi, K., Watanabe, N., Yamada, T., Toyama, Y., Tezuka, K., and Hozumi, N. (2005) *J. Bone Miner. Metab.* **23**, 270–273
- Hoffman, L. M., Garcha, K., Karamboulas, K., Cowan, M. F., Drysdale, L. M., Horton, W. A., and Underhill, T. M. (2006) *J. Cell Biol.* **174**, 101–113
- Stanton, L. A., Underhill, T. M., and Beier, F. (2003) *Dev. Biol.* **263**, 165–175
- Nakamura, K., Shirai, T., Morishita, S., Uchida, S., Saeki-Miura, K., and Makishima, F. (1999) *Exp. Cell Res.* **250**, 351–363
- Oh, C. D., Chang, S. H., Yoon, Y. M., Lee, S. J., Lee, Y. S., Kang, S. S., and Chun, J. S. (2000) *J. Biol. Chem.* **275**, 5613–5619
- Katagiri, T., Imada, M., Yanai, T., Suda, T., Takahashi, N., and Kamijo, R. (2002) *Genes Cells* **7**, 949–960
- Korchynskyi, O., and ten Dijke, P. (2002) *J. Biol. Chem.* **277**, 4883–4891
- Raingaud, J., Whitmarsh, A. J., Barrett, T., Derjard, B., and Davis, R. J. (1996) *Mol. Cell Biol.* **16**, 1247–1255
- Fukuda, T., Scott, G., Komatsu, Y., Araya, R., Kawano, M., Ray, M. K., Yamada, M., and Mishina, Y. (2006) *Genesis* **44**, 159–167
- Liao, P., Georgakopoulos, D., Kovacs, A., Zheng, M., Lerner, D., Pu, H., Saffitz, J., Chien, K., Xiao, R. P., Kass, D. A., and Wang, Y. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 12283–12288
- Zhang, R., Murakami, S., Coustry, F., Wang, Y., and de Crombrughe, B. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 365–370
- Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A., and de Crombrughe, B. (2002) *Genes Dev.* **16**, 2813–2828
- Yoon, B. S., Pogue, R., Ovchinnikov, D. A., Yoshii, I., Mishina, Y., Behringer, R. R., and Lyons, K. M. (2006) *Development (Camb.)* **133**, 4667–4678
- Tsumaki, N., and Yoshikawa, H. (2005) *Cytokine Growth Factor Rev.* **16**, 279–285
- Wang, G., and Beier, F. (2005) *J. Bone Miner. Res.* **20**, 1022–1031
- Pelton, R. W., Dickinson, M. E., Moses, H. L., and Hogan, B. L. (1990) *Development (Camb.)* **110**, 609–620

Characteristics of fracture and related factors in patients with rheumatoid arthritis

Akihide Nampei · Jun Hashimoto · Junichiro Koyanagi · Takeshi Ono · Hideo Hashimoto · Noriyuki Tsumaki · Tetsuya Tomita · Kazuomi Sugamoto · Norihiro Nishimoto · Takahiro Ochi · Hideki Yoshikawa

Received: 14 September 2007 / Accepted: 14 November 2007 / Published online: 23 February 2008
© Japan College of Rheumatology 2008

Abstract To examine the clinical features of vertebral and non-vertebral fractures in patients with rheumatoid arthritis (RA), including insufficiency fractures, and to assess the risk factors for fracture, we prospectively studied 209 outpatients with rheumatoid arthritis for 1 year. The age, gender, Steinbrocker's functional class, glucocorticoid use, history of lower limb surgery, serum C-reactive protein (CRP), and use of bisphosphonates were evaluated. Examination for fractures was performed by radiography, computed tomography (CT), magnetic resonance imaging (MRI), and bone scanning. Thirty-three fractures occurred in 24 patients over the 1-year study period, and the incidence was 15.8 fractures per 100 patient-years. Fractures occurred at various sites. The majority (70%) was insufficiency fracture, and more than 50% caused ambulatory dysfunction. Radiographic findings were absent in 39% of the fractures at the onset of pain. The functional class and glucocorticoid dose were significantly associated with fracture development. This prospective study showed that the incidence of fractures, especially insufficiency fractures, was very high in patients with rheumatoid arthritis

and that most of their fractures caused gait disturbance. Early intervention to prevent secondary osteoporosis is recommended to maintain the quality of life in patients with rheumatoid arthritis, especially those with functional impairment or undergoing glucocorticoid therapy.

Keywords Fracture · Incidence · Insufficiency fracture · Rheumatoid arthritis · Risk factor

Introduction

Patients with rheumatoid arthritis (RA) have a greater risk of osteoporosis and fracture than the general population, because of impaired walking ability, inflammation due to their disease, and glucocorticoid use. Fractures influence the morbidity and mortality of patients with primary osteoporosis, and some reports have demonstrated that the risk of vertebral or hip fractures is higher in patients with RA than in those with primary osteoporosis [1–5]. Several previous studies have revealed that many osteoporotic fractures occur at sites other than the spine and proximal femur in patients with RA [6–10]. Although those studies assessed the incidence of fractures, including fractures other than those of the spine and hips, most of them were performed retrospectively. On the other hand, several reports have emphasized the occurrence of pelvic or juxta-articular insufficiency fractures in patients with RA [11–15], but no study has yet clarified the incidence of insufficiency fracture in this disease. Insufficiency fractures are difficult to detect clinically without careful examination and appropriate radiological investigation based on a suspected diagnosis [16], making a retrospective study design not adequate to evaluate the occurrence of such fractures. Recently, a large-scale, population-based, cohort study

A. Nampei · J. Hashimoto (✉) · J. Koyanagi · T. Ono · H. Hashimoto · N. Tsumaki · T. Tomita · K. Sugamoto · H. Yoshikawa
Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan
e-mail: junha@ort.med.osaka-u.ac.jp

N. Nishimoto
Laboratory of Immune Regulation, Osaka University Graduate School of Frontier Bioscience, 1-3 Yamadaoka, Suita 565-0871, Japan

T. Ochi
Osaka Police Hospital, 10-31 Kitayama-cho, Tennoji-ku, Osaka 543-0035, Japan

performed in the UK [9] and a large-scale, prospective, observational study performed in Japan [10] were reported, but those studies were based on medical records and self-reporting by questionnaire, in which insufficiency fractures might also have been overlooked. A prospective study design and detection of fractures through careful clinical assessment by orthopaedic surgeons are recommended to clarify the actual characteristics of fractures affecting RA patients.

Therefore, we conducted a prospective study to investigate the actual incidence of fracture for all skeletal sites, including insufficiency fractures, and to assess the clinical presentation and risk factors for fracture in RA patients.

Materials and methods

Patients and study protocol

This prospective study enrolled subjects undergoing regular outpatient review at intervals of less than 3 months to avoid missing fractures. A total of 209 outpatients (31 men and 178 women) with RA according to the American College of Rheumatology 1987 revised classification criteria [17] were entered into the study at Osaka University

Hospital. The prospective follow-up period was 1 year from October 2003 to September 2004. The baseline characteristics of the patients are shown in Table 1 and include age, gender, duration of RA, serum C-reactive protein (CRP) level for assessment of disease activity, functional class (Steinbrocker's criteria [18]), surgical treatment of gait disturbance, glucocorticoid use (daily dose and duration), and bisphosphonate therapy for more than 2 years. Surgery for gait disturbance included total hip arthroplasty in 28 patients (nine bilateral), total knee arthroplasty in 64 patients (41 bilateral), total ankle arthroplasty in eight patients (two bilateral), hindfoot surgery in 14 patients (five bilateral), and forefoot surgery in 34 patients (14 bilateral). Ninety-two patients underwent lower limb surgery, and 61 patients had more than two operations. The sites of fracture, incidence of fracture, circumstances under which fractures occurred, and radiographic findings were evaluated. When more than two vertebral fractures occurred on one occasion, they were counted as one fracture. Circumstances were classified as no trauma (insufficiency fracture), minor trauma (such as a fall), or major trauma (such as a traffic accident). Insufficiency fracture was defined as fracture occurring in abnormal bone already weakened by decreased mineralization and with insufficient elastic resistance [16, 19].

Table 1 Baseline characteristics of 209 patients with RA

Variables	Value	Number of patients
Age (years) (mean \pm SD)	60.4 \pm 11.5	
Gender		
Male (%)	14.8	31
Female (%)	85.2	178
Disease duration (years) (mean \pm SD)	14.5 \pm 10.2	
Disease activity (CRP) (mean \pm SD)	2.0 \pm 2.4	
Functional class		
I (%)	43.5	91
II (%)	41.6	87
III (%)	14.8	31
IV (%)	0	0
Surgical treatment of lower legs (%)	45.9	96
Glucocorticoid use		
Current users (%)	74.2	155
Daily dose (mg/day) (mean \pm SD)	5.94 \pm 3.45	
Duration (years)		
None (%)	23.4	49
0–2 years (%)	14.8	31
2–5 years (%)	19.6	41
5–10 years (%)	29.2	61
10 years \leq (%)	12.9	27
Bisphosphonate use		
None or \leq 2 years (%)	77.5	162
> 2 years (%)	22.5	47

RA rheumatoid arthritis, CRP C-reactive protein
Functional classes according to Steinbrocker criteria

Fractures that occurred during normal daily activities without any trauma were considered to be insufficiency fractures.

Diagnosis of fracture

When patients presented to the hospital with pain, a single orthopaedic surgeon (J.H.) examined them for fractures. Detection of fractures was initially performed by careful clinical examination and plain radiography. In the absence of radiographic findings, magnetic resonance imaging (MRI), computed tomography (CT), bone scanning, and longitudinal radiographic changes were used for diagnosis.

Statistical analysis

Risk factors associated with the occurrence of fracture were evaluated. Those shown in Table 1 were assessed by univariate analysis using SPSS version 11.5 J software (SPSS Inc., Chicago, IL, USA), and the odds ratios and 95% confidence intervals (CI) were calculated. Subsequently, multivariate logistic regression analysis was performed for the factors that were significant according to univariate analysis. The level of significance was set at $P < 0.05$ for all tests.

Results

Incidence and characteristics of fractures

We detected 33 fractures in 24 patients during the 1 year follow-up period. The incidence of fractures was 15.8 per 100 patient-years, and the incidence of patients with new fractures was 11.5 per 100 patient-years. Fractures occurred at various sites, including the rib, vertebra, pelvis, humerus, elbow, femur, knee, and foot (Table 2). All fractures affecting the pelvis and lower extremities, as well as one of four fractures involving the lumbar spine, resulted in ambulatory dysfunction (54.5%). The fracture occurred with no trauma (insufficiency fracture) in 23 cases (69.7%), and with minor trauma (fall) in ten cases (30.3%). There were no fractures due to major trauma (Table 2). Twenty fractures (60.6%) could be diagnosed by plain radiography at the onset of pain, while 13 fractures (39.4%) could not be detected on plain radiographs at that time (Table 2). MRI, CT, bone scanning, and longitudinal radiography were able to detect these 13 fractures. Among the 24 patients suffering fractures, nine had not received any prior surgical treatment, 15 had undergone lower limb surgery (two had total hip arthroplasty, nine had total knee arthroplasty, one had total ankle arthroplasty, four had

Table 2 Fracture sites, circumstances, and radiographic change at onset of pain

Fracture site	Total number	Circumstance		Radiographic change	
		Minor trauma	Insufficiency fracture	Present	Absent
Ribs	2	0	2	2	0
Shoulder	4	4	0	4	0
Elbow	1	1	0	1	0
Spine	9	1	8	7	2
Sacrum	3	0	3	0	3
Pubis	5	0	5	2	3
Ilium	1	1	0	0	1
Hip	1	1	0	0	1
Femur	2	2	0	2	0
Knee	3	0	3	0	3
Foot, ankle	2	0	2	2	0
Total	33	10	23	20	13

hindfoot surgery, and seven had forefoot surgery), and eight patients had undergone more than two lower limb operations.

Risk factors for fracture

Univariate analysis comparing patients with and without fractures was performed as an aid to selecting variables for inclusion in subsequent multivariate analysis. Among the variables investigated, functional class and glucocorticoid use (daily dose and duration) showed a significant difference ($P < 0.05$), while age and lower limb surgery showed borderline significance ($P < 0.1$) (Table 3). Variables that showed $P < 0.1$ on univariate analysis were included in the subsequent multivariate analysis. The results of multivariate logistic regression analysis showed that daily glucocorticoid use and functional class were significantly associated with the risk of fracture in RA patients (Table 3). Using the same process, we found that the only significant risk factor for vertebral fractures was the daily glucocorticoid dose according to multivariate analysis (Table 3). On the other hand, analysis of the risk factors for pelvis/lower limb fractures revealed that only functional class was a significant predictor by multivariate analysis (Table 3). No risk factor was significantly correlated with fracture of the upper limbs (data not shown). Figure 1 shows the incidence of fractures stratified according to functional impairment. The incidence of all fractures tended to increase as the functional status deteriorated. Fractures of the upper limbs occurred in only stage I and

Table 3 Possible risk factors for fracture in RA patients

Variables	P	Odds ratio	95% CI
All fractures			
Univariate logistic regression			
Age	0.057	1.040/year	0.999–1.084
Functional class	0.001	2.963/ class	1.598–5.496
Glucocorticoid use			
Daily dose	0.003	1.174/mg	1.054–1.306
Duration	0.019	1.095/year	1.015–1.181
Surgical treatment of lower legs	0.089	2.140/site	0.891–5.138
Multivariate logistic regression			
Functional class	0.020	2.277/ class	1.136–4.562
Glucocorticoid use			
Daily dose	0.034	1.141/mg	1.010–1.290
Vertebral fractures			
Univariate logistic regression			
Age	0.056	1.084/year	0.998–1.177
Glucocorticoid use			
Daily use	0.034	1.212/mg	1.014–1.449
Multivariate logistic regression			
Glucocorticoid use			
Daily use	0.032	1.232/mg	1.018–1.492
Fractures of pelvis and lower legs			
Univariate logistic regression			
Functional class	0.001	4.987/ class	2.032–12.237
Glucocorticoid use			
Daily use	0.010	1.195/mg	1.043–1.370
Duration	0.008	1.131/year	1.033–1.239
Surgical treatment of lower legs	0.093	2.819/site	0.840–9.463
Multivariate logistic regression			
Functional class	0.007	3.924/ class	1.462–10.535

CI confidence interval

stage II patients, while fractures of the pelvis/lower limbs and vertebra occurred in stage II and stage III patients. The incidence of pelvic/lower limb fractures increased along with functional deterioration.

Discussion

We performed our prospective study of 209 outpatients with RA to investigate the characteristics of fractures in this disease. We found that the incidence of fracture, including non-vertebral and insufficiency fractures, was very high in RA, being 15.8 fractures per 100 patient-years and 11.5 patients per 100 patient-years. These incidence




Fig. 1 Fracture incidence stratified by functional impairment. The incidence of all fractures increased along with the severity of functional impairment. Upper limb fractures tended to occur in relatively mild RA, but the association was not significant, and vertebral fractures were not associated with functional status. On the other hand, fractures of the lower limbs and pelvis were significantly more common as the functional status deteriorated. I, II, and III refer to Steinbrocker's functional classes

rates were higher than those reported previously, which were 1.57 fractures per 100 patient-years [7], 1.62 fractures per 100 patient-years (non-vertebral fractures) [8], 1.07 fractures per 100 patient-years [9], 1.68 fractures per 100 patient-years [10], and 3.59 fractures per 100 patient-years [20]. However, all of those previous studies were retrospective and depended on medical records, radiology reports, telephone interviews, or questionnaires. In our prospective study, fracture diagnosis was made by careful assessment of symptoms and signs by a single experienced rheumatologist along with adequate diagnostic imaging, because insufficiency fractures or juxta-articular fractures are difficult to detect in RA patients without careful examination and appropriate radiological investigation based on a high index of suspicion [16]. Thus, misdiagnosis and failure to detect insufficiency fractures or juxta-articular fractures were thought to be minimized in our study. This difference in methodology probably explains a large part of the difference in the incidence of fractures between our study and previous studies.

Another possible reason for the discrepancy may be differences in the background factors of the subjects. Our patients all had relatively severe RA and regularly attended a university hospital; 74.2% used oral corticosteroids, and approximately half of them had undergone major surgery on the lower limbs (total hip arthroplasty and/or total knee arthroplasty). Steroid use was varied in previous studies (58% [7], 47.8% [8], 25% [9], 61% [10]), but was lower than in our series, and it has been reported that 71% of patients who develop fractures have taken steroids [20]. In the most recent study [10], 22.5% of patients had a history of orthopedic surgery and 8.9% had a history of total knee arthroplasty, while 44% of our patients had received lower

limb surgery (excluding those with upper limb or spinal surgery) and 30.6% had undergone total knee replacement. Differences in the severity of RA, and different levels of corticosteroid use, might have influenced the incidence of fracture, making it inappropriate for our findings to be compared directly with those of other general cohort studies.

Our study showed four characteristic features of fractures occurring in patients with RA. The first was, as previously reported, that fractures may occur at various sites throughout the entire skeleton [6–10], including the ribs, upper and lower limbs, vertebrae, and pelvis, while hip and vertebral fractures predominate in patients with primary osteoporosis. This finding indicates that RA patients may suffer from both generalized osteoporosis and juxta-articular osteoporosis. The second point was that insufficiency fractures, which are caused by normal physiological stress, are the most common type of fracture (69.7%) in patients with RA. It has been reported that RA is one of the most common underlying diseases in patients with insufficiency fracture [11–15], and there have been many case reports of insufficiency fractures in RA patients [21–23], but the frequency of these fractures has been unclear. In our study, misdiagnosis and the overlooking of insufficiency fractures or juxta-articular fractures were presumably minimized. The third point was that fractures undetectable by plain radiography at the onset of pain are very common (39.4%). Among the insufficiency fractures, 47.8% could not be seen on the first plain radiograph obtained at the onset of pain (data not shown). Fractures of the upper extremity were caused by trauma and were radiologically apparent. Most of the vertebral and pelvic fractures were insufficiency fractures, but the former were relatively apparent on plain radiographs, and the latter were mostly undetectable by radiography. Long-bone fractures of the lower limbs were apparent on plain radiographs, but fractures of the knee and hip joints were frequently undetectable. According to previous reports, pelvic fractures are frequently insufficiency fractures [13, 24–26], with CT and MRI being more reliable methods for diagnosis than plain radiography [19, 26, 27]. Bone scanning is also useful for detection of sacral insufficiency fractures [28]. In our series, CT, MRI, and bone scanning were all useful, especially for pelvic fractures and peri-articular fractures. Thus, it is important to suspect the presence of an insufficiency fracture based on the results of meticulous physical examination, and such fractures will often be undetectable on plain radiographs in patients with RA. The fourth point was that the 54.5% of the fractures resulted in ambulatory dysfunction. This shows that prevention of fractures is important in patients with RA to maintain their mobility, just as prevention of joint destruction by anti-rheumatic therapy is important.

According to prior reports, the risk factors for fracture in RA patients are age, gender, low body mass index (BMI), ambulatory dysfunction, corticosteroid use [6, 7], bone mineral density [8], and joint deformity [15]. Our multivariate analysis showed that daily glucocorticoid use and functional class were significant overall risk factors for fracture in RA patients (Table 3). Analyzing the risk factors by site, we found that daily glucocorticoid use was a significant risk factor for vertebral fractures, but not for pelvic and lower limb fractures. This result is consistent with previous reports that vertebral fractures are significantly associated with daily glucocorticoid use [3, 29]. Our study also showed that functional class was a significant risk factor for pelvic and lower limb fractures, but not for vertebral fractures. Corticosteroid use, severe osteoporosis, and joint deformity have also been reported as risk factors of pelvic and lower limb fractures [15, 30]. Relationships between functional disturbance and hip fracture [31], wrist and hip fractures [32], and any type of fracture [33] have all been reported previously. Our findings did not contradict those previous reports and, additionally, showed that functional impairment is a stronger risk factor than glucocorticoid use for pelvic and lower limb fractures. Figure 1 shows the fracture incidence in relation to Steinbrocker's functional classification. The incidence of all fractures, as well as fractures of the pelvis and lower limbs, increased along with functional impairment. However, the incidence of upper limb and vertebral fractures was not correlated with the functional class. This suggests that greater mechanical stress due to weight bearing or ambulation is quite important to protect the pelvis and lower limbs from bone fragility.

Our study had several limitations. First, our subjects had relatively severe disease, with their physical function being worse than in others and half of them had undergone major lower limb surgery, and the rate of oral glucocorticoid use was high. Also, some possible risk factors for fracture were not evaluated in this study, such as bone mineral density, body mass index, fracture history, other medications for osteoporosis and RA, alcohol, and smoking. Third, we only evaluated painful fractures, without counting asymptomatic fractures (especially vertebral fractures). Since asymptomatic vertebral fractures and deformities are common in patients with primary osteoporosis [29, 34–37] as well as RA [38], our study would have underestimated the total fracture incidence by excluding painless vertebral fractures.

In conclusion, we prospectively investigated the characteristics of fractures, the overall fracture incidence, and risk factors for fracture (including insufficiency fracture) in RA patients over a 1-year period. The incidence of fracture was relatively high, and any site could be affected. In addition, 55% of the fractures caused gait impairment, 70%

were insufficiency fractures, and 39% were not detectable by plain radiography at the onset of pain. Significant risk factors for fracture were functional disability and glucocorticoid use. Early intervention to prevent secondary osteoporosis is important to avoid fractures and maintain the quality of life in patients with RA, especially those with functional impairment or glucocorticoid use.

Acknowledgments This work was supported by a Health Science Research Grant from the Ministry of Health and Welfare of Japan.

References

- Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. *Ann Rheum Dis* 1995;54:801–6.
- Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. *BMJ* 1993;306:558.
- de Nijs RN, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2001;40:1375–83.
- Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. *Ann Rheum Dis* 1995;54:49–52.
- Huuskio TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. *Ann Rheum Dis* 2001;60:521–2.
- Hooyman JR, Melton LJ 3rd, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis. A population-based study. *Arthritis Rheum* 1984;27:1353–61.
- Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. *J Rheumatol* 1993;20:1666–9.
- Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. *Ann Rheum Dis* 2004;63:177–82.
- van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum* 2006;54:3104–12.
- Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. *J Rheumatol* 2007;34:303–10.
- Schneider R, Kaye JJ. Insufficiency and stress fractures of the long bones occurring in patients with rheumatoid arthritis. *Radiology* 1975;116:595–9.
- Fam AG, Shuckett R, McGillivray DC, Little AH. Stress fractures in rheumatoid arthritis. *J Rheumatol* 1983;10:722–6.
- West SG, Troutner JL, Baker MR, Place HM. Sacral insufficiency fractures in rheumatoid arthritis. *Spine* 1994;19:2117–21.
- Young A, Kinsella P, Boland P. Stress fractures of the lower limb in patients with rheumatoid arthritis. *J Bone Joint Surg Br* 1981;63:239–43.
- Alonso-Bartolome P, Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V. Insufficiency fractures of the tibia and fibula. *Semin Arthritis Rheum* 1999;28:413–20.
- Pentecost RL, Murray RA, Brindley HH. Fatigue, insufficiency, and pathologic fractures. *JAMA* 1964;187:1001–4.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
- Steinbrocker O, Traeger C, Batterman R. Therapeutic criteria in rheumatoid arthritis. *JAMA* 1949;140:659–62.
- Cooper KL, Beabout JW, Swee RG. Insufficiency fractures of the sacrum. *Radiology* 1985;156:15–20.
- Sakao K, Tokunaga D, Fujioka M, Watanabe Y, Ikoma K, Kubo T. Analysis of fractures in patients with rheumatoid arthritis (in Japanese). *Kosetsu* 2003;25:429–31.
- Lloyd ME, Davitt S, Hall JR. Bilateral tibia and fibula fractures in a patient with rheumatoid arthritis. *Clin Rheumatol* 2001;20:270–2.
- Vanhoof J, Landewe S, Vandevenne J, Geusens P. An exceptional radiographic presentation of bilateral insufficiency fractures of the proximal tibia in a patient with rheumatoid arthritis. *Ann Rheum Dis* 2003;62:277–9.
- Wild A, Jaeger M, Haak H, Mehdian SH. Sacral insufficiency fracture, an unsuspected cause of low-back pain in elderly women. *Arch Orthop Trauma Surg* 2002;122:58–60.
- Peh WC, Gough AK, Sheeran T, Evans NS, Emery P. Pelvic insufficiency fractures in rheumatoid arthritis. *Br J Rheumatol* 1993;32:319–24.
- Godfrey N, Staple TW, Halter D, Lorber A. Insufficiency os pubis fractures in rheumatoid arthritis. *J Rheumatol* 1985;12:1176–9.
- Soubrier M, Dubost JJ, Boisgard S, Sauvezie B, Gaillard P, Michel JL, et al. Insufficiency fracture. A survey of 60 cases and review of the literature. *Joint Bone Spine* 2003;70:209–18.
- Blake SP, Connors AM. Sacral insufficiency fracture. *Br J Radiol* 2004;77:891–6.
- Ries T. Detection of osteoporotic sacral fractures with radio-nuclides. *Radiology* 1983;146:783–5.
- Orstavik RE, Haugeberg G, Uhlig T, Falch JA, Halse JI, Hoiseth A, et al. Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. *Arthritis Rheum* 2003;49:355–60.
- Maenpaa HM, Soini I, Lehto MU, Belt EA. Insufficiency fractures in patients with chronic inflammatory joint diseases. *Clin Exp Rheumatol* 2002;20:77–9.
- Ma J, Markides KS, Perkowski LP, Stroup-Benham CA, Lichtenstein M, Goodwin JS. Impact of selected medical conditions on self-reported lower-extremity function in Mexican-American elderly. *Ethn Dis* 1998;8:52–9.
- Stel VS, Pluijm SM, Deeg DJ, Smit JH, Bouter LM, Lips P. Functional limitations and poor physical performance as independent risk factors for self-reported fractures in older persons. *Osteoporos Int* 2004;15:742–50.
- Colon-Emeric CS, Pieper CF, Artz MB. Can historical and functional risk factors be used to predict fractures in community-dwelling older adults? Development and validation of a clinical tool. *Osteoporos Int* 2002;13:955–61.
- Kleerekoper M, Nelson DA. Vertebral fracture or vertebral deformity. *Calcif Tissue Int* 1992;50:5–6.
- Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. *J Bone Miner Res* 1992;7:221–7.
- Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate

- on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. *Lancet* 1996; 348:1535–41.
37. Ross PD. Clinical consequences of vertebral fractures. *Am J Med* 1997;103:30S–42S (discussion 42S–3S).
38. Arai K, Hanyu T, Sugitani H, Murai T, Fujisawa J, Nakazono K, et al. Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. *J Bone Miner Metab* 2006;24:118–24.



Inflammatory osteoclastogenesis can be induced by GM-CSF and activated under TNF immunity

Koji Nomura, Shoko Kuroda, Hideki Yoshikawa, Tetsuya Tomita*

Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan

Received 22 December 2007

Available online 15 January 2008

Abstract

In inflammatory arthritis such as RA, osteoclastic activity is severely enhanced. GM-CSF was reportedly elevated in synovial fluid, but is a strong inhibitor of osteoclastogenesis; here lies a contradiction. Our objective was to examine what type of osteoclasts generate and resorb bone with resistance to GM-CSF in an inflammatory joint. Monocyte-derived cells generated in GM-CSF were morphologically and immunophenotypically different from both the conventional DC and macrophage. They could differentiate into osteoclasts in the presence of RANKL + M-CSF, acquiring a stronger osteoclastic activity under TNF treatment. Furthermore, their differentiation was not inhibited by GM-CSF, while monocyte-derived osteoclast differentiation was completely inhibited. The resorption was suppressed by GM-CSF, and the existence of another osteoclastic pathway has been suggested. Our findings indicate another type of osteoclast exists in inflammatory arthritis.

© 2008 Elsevier Inc. All rights reserved.

Keywords: Osteoclastogenesis; Inflammation; GM-CSF; TNF α ; Rheumatoid arthritis

Osteoclasts are the multinuclear cells specialized for bone resorption, playing a crucial role in bone remodeling [1,2]. Osteoclasts have been known to differentiate from hematopoietic precursors of the monocyte/macrophage lineage in the presence of macrophage-colony stimulating factor (M-CSF or CSF-1) and receptor activator of NF- κ B ligand (RANKL) [3–6]. However, the accurate lineage of osteoclast precursors remains uncertain, and it is unclear whether there are any osteoclast varieties.

Both rheumatoid arthritis (RA) and osteoporosis are major adult skeletal diseases that are due to excessive osteoclastic activity, leading to an imbalance of bone remodeling in favor of bone resorption [7,8]. There are big differences among these diseases and their pathogenesis. The environment where osteoclasts generate and work may partially explain these discrepancies; RA involves inflammation while osteoporosis does not. It is unknown,

however, whether inflammation will affect osteoclastogenesis in RA.

Tumor necrosis factor- α (TNF α), Interleukin-1 (IL-1), M-CSF, GM-CSF, interferon- γ (IFN γ) and IL-18 are the representative pro-inflammatory cytokines that are characteristic of RA [7,9]. Though TNF α and IL-1 have been known to stimulate osteoclastogenesis, GM-CSF, IFN γ and IL-18 reportedly have an inhibitory effect on osteoclastogenesis [10–15]. This is a contradiction in 'inflammatory' osteoclastogenesis. Recently it has reported that IL-17-producing helper T cell subset (Th17) is responsible for bone destruction in RA [16,17]. Th17 immunity may well explain this contradiction. However Th17 immunity in RA is controversial and the actual elevation of GM-CSF and IL-18 in RA synovial fluid cannot be neglected [18,19].

GM-CSF was initially defined by its ability to generate granulocyte and macrophage colonies from precursor cells in vitro [20]. But GM-CSF is difficult to detect in steady state circulation and GM-CSF-deficient mice showed no obvious deficiency in the numbers of myeloid cells.

* Corresponding author. Fax: +81 6 6879 3559.

E-mail address: tomita@ort.med.osaka-u.ac.jp (T. Tomita).

Therefore, GM-CSF seems to have another function at the non-steady state, particularly in inflammation [21,22]. In fact, upon appropriate stimulation and other pro-inflammatory cytokines, much of the production and action of GM-CSF occurs locally at the site of inflammation [23].

What role does GM-CSF play in 'inflammatory' osteoclastogenesis? Is there truly an inhibitory effect towards osteoclastogenesis?

Considering anti-GM-CSF therapy decreased the disease severity and reduced the levels of TNF α and IL-1 in inflammatory joint or block post-onset collagen induced arthritis, GM-CSF is not expected to have such an inhibitory property in 'inflammatory' osteoclastogenesis [24,25]. Considering IL-18 induced GM-CSF, not IFN γ , production in primary osteoblasts, GM-CSF must have some promotive function in 'inflammatory' osteoclastogenesis, resulting in severe bone destruction [26].

We hypothesized that osteoclasts in the inflammatory state are different from those charged in bone remodeling in the non-inflammatory state. Therefore, GM-CSF can be a potential cytokine for 'inflammatory' osteoclastogenesis in place of M-CSF, which can generate the monocyte/macrophage populations into osteoclast precursors.

In this study, we investigated the property of monocyte-derived osteoclast precursors generated in GM-CSF and analyzed their osteoclastic activity under TNF immunity. Then we found that their differentiation could not be inhibited by GM-CSF. These cells acquire a stronger osteoclastic activity by TNF α treatment.

Materials and methods

Cell purification, culture, and reagents. Mononuclear cells (PBMCs) were isolated from peripheral blood of healthy adult volunteers by Ficol-Paque (Amersham Biosciences, Tokyo, Japan) density gradient centrifugation. Monocytes were purified using CD14 Microbeads (Miltenyi Biotec, Auburn, CA) and subsequently cultured during 7 days in 24-well plates ($5-6 \times 10^5$ cells/ml) in RPMI1640 (Gibco/BRL, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 IU/ml penicillin and 100 μ g/ml streptomycin (Gibco/BRL) in the presence of 50 ng/ml recombinant human (rh)GM-CSF, 10 ng/ml rhTNF α + 50 ng/ml rhGM-CSF, 50 ng/ml rhIL-4 + 50 ng/ml rhGM-CSF, or 50 ng/ml rhM-CSF, respectively. Recombinant human IL-4, TNF α , GM-CSF and M-CSF were purchased from PeproTech (London, UK).

Flow cytometry. The phenotype of cells was analyzed by flow cytometry using a FACS Calibur (Becton Dickinson, San Jose, CA). For monocyte-derived cells, the following mAbs were used; fluorescein isothiocyanate (FITC)-labeled anti-CD80, anti-CD11b, anti-CD14, and PE-Cy5 (PC5)-labeled anti-CD86 (Biolegend, San Diego, CA). Results were expressed in mean fluorescence intensity (MFI) values of total positive cells. At least 10,000 cells per sample were analyzed.

Osteoclast differentiation and TRAP assay. Monocyte-derived cells were seeded at 1×10^5 cells/ml per well in Lab-Tek 16 well chamber slides (Nalge Nunc, Rochester, NY) in α -minimum essential medium (α -MEM) (Gibco/BRL) supplemented with 10% FBS, 100 U/ml penicillin and 100 μ g/ml streptomycin in the presence of 25 ng/ml M-CSF and 100 ng/ml sRANKL (PeproTech) for 14 days. For some experiments, 0.1 ng/ml or 1 ng/ml GM-CSF was co-treated in the culture media during the assay. Media were changed every three days. Then the cells were washed and stained with TRAP stain kit (Cell Garage, Tokyo, Japan). The number of TRAP positive multinuclear (three or more nuclei) cells was counted.

Bone resorption assay. To assess resorption ability, monocyte-derived cells were cultured on carbonated calcium phosphate coated plate (OAS Osteoclast Activity Assay Substrate; OCT, Choongnam, Korea) or on




Fig. 1. The characterization of myeloid cells generated in GM-CSF or TNF α + GM-CSF from CD14 + monocytes. Inverted phase contrast microscopic pictures of monocytes cultured in the presence of (A) GM-CSF, (B) TNF α + GM-CSF, (C) IL-4 + GM-CSF (cDC), or (D) M-CSF (macrophage) for 7 days. (original magnifications: $\times 400$).

dentine slices (Wako, Osaka, Japan). The technique of osteoclast differentiation was described above. Finally cells were washed vigorously and the calcified matrix resorption on each well was measured with a Win Roof image analyzer (Mitani, Fukui, Japan). Dentine slices were stained with Mayer's hematoxylin solution (Wako) to detect resorption pits under light microscopy.

Immunofluorescence staining. Cells cultured on glass chamber slides were fixed for 15 min with 4% paraformaldehyde in PBS and then permeabilized with TBST for 15 min. After blocking for 60 min with 5% skim milk in TBST, cells were incubated with anti-cathepsin K (goat polyclonal; Santa Cruz Biotechnology, CA) or rhodamine-labeled phalloidin (Sigma-Aldrich, St. Louis, MO). Slides were then treated with the appropriate conjugated secondary antibodies (Invitrogen Molecular Probes, Carlsbad,

CA). Primary antibodies were applied overnight at 4 °C and secondary antibodies were applied for 60 min at room temperature in a humidified chamber. DNA nuclei were stained with DAPI. Between each step, slides were washed three times for 5 min in TBST. Samples were examined under a confocal laser-scanning microscope (Eclipse E800M; Nikon).

Statistical analysis. Data were expressed as means \pm SD. Sample values below the detection limit for the assay were regarded as negative and assigned a value of 0. Statistical analysis was performed using the Student's *t*-test or the Mann-Whitney U test, where appropriate according to the distribution data. $p < 0.05$ was considered statistically significant.

Results

Osteoclast precursors generated in GM-CSF or TNF α + GM-CSF were different from cDC or macrophage

We first examined how myeloid cells were generated in GM-CSF or TNF α + GM-CSF. Exposure of CD14 positive monocytes to GM-CSF or TNF α + GM-CSF in seven days lead to adherent cells with small projections (Figs. 1A and B). These cells displayed a distinguishable morphology while the conventional dendritic cell (cDC) treated with IL-4 + GM-CSF displayed typical non-adherent dendritic morphology (Fig. 1C) and macrophage treated with M-CSF displayed an adherent various morphology (Fig. 1D).

Table 1
Immunophenotypical analysis of cells

	IL4 + GM-CSF	GM-CSF	TNF + GM-CSF	M-CSF
CD80	95.7 \pm 29.6	82.3 \pm 7.4	59.3 \pm 9.5	268.0 \pm 52.5
CD86	107.7 \pm 7.8	131.0 \pm 39.6	167.0 \pm 33.4	232.0 \pm 41.4
CD14	79.0 \pm 20.9	914.0 \pm 264.0	370.0 \pm 170.0	1350.0 \pm 80.2
CD11b	89.0 \pm 21.0	104.0 \pm 18.6	72.0 \pm 18.7	279.0 \pm 43.5

Table summarizes the phenotype of myeloid cells generated in IL-4 + GM-CSF, in GM-CSF, in TNF α + GM-CSF, and in M-CSF after 7 days culture. MFI of all the positive cells is shown as means \pm SD from three independent experiments.




Fig. 2. RANKL + M-CSF induce differentiation of GM-OP and TNF-OP into osteoclasts. Osteoclastogenesis cultures treated with sRANKL (100 ng/ml) and M-CSF (25 ng/ml) for 14 days. (A) Representative figures of GM-OP-derived osteoclasts and TNF-OP-derived osteoclasts were shown in TRAP stain (top), on carbonated calcium phosphate coated plate (middle), and on dentine slices (bottom). (B) After 14 days the number of TRAP-positive MGCs (three or more nuclei) per well was counted. Results are expressed as means \pm SD ($p < 0.005$). (C) After 14 days the resorption area on carbonated calcium phosphate coated plate was calculated. Results are expressed as means \pm SD ($p < 0.05$).

These cells expressed CD80+CD86+CD11b+, similar to cDC (Table 1). However, CD14 expression was much higher than cDC and no less than the macrophage. They were morphologically and immunophenotypically distinguished from both cDC and macrophage, and thought to be another lineage of myeloid cells.

Two myeloid cells could differentiate into osteoclasts

To examine how myeloid cells can differentiate into osteoclasts, we treated these cells with RANKL and M-CSF. After 14 days treatment, multinucleated giant cells (MGCs) exhibiting intense TRAP activity were formed (Fig. 2A). Interestingly the sizes of osteoclasts were smaller than monocyte-derived osteoclast, with easily distinguishable morphology (Fig. 4A).

The number of TRAP positive MGCs derived from TNF α + GM-CSF treated cells (TNF-OP) was significantly larger than that of MGCs from GM-CSF treated cells (GM-OP). (TNF-OP 259 \pm 68/well; GM-OP 167 \pm 38/well; $p < 0.005$) (Fig. 2B). They also formed typical resorption pits and tracks on dentine slices, indicating that they were functional mobile osteoclasts (Fig. 2A). The resorption area of calcium phosphate coated plate on TNF-OP derived OC and GM-OP derived OC was 26.1 \pm 13.0% and 16.1 \pm 4.13%, respectively (Fig. 2C). The resorption area of TNF-OP derived OC was significantly larger than GM-OP derived OC ($p < 0.05$).

From immunofluorescence staining, both GM-OP derived OC and TNF-OP derived OC exhibited characteristic osteoclastic belts of actin podosomes and Cathepsin-K (CATK) expression (Fig. 3).

In this way under RANKL + M-CSF treatment, both TNF-OP and GM-OP could differentiate functionally and phenotypically into osteoclasts.

GM-CSF did not inhibit their osteoclast differentiation, but inhibited resorption ability

To clarify whether TNF-OP and GM-OP are not inhibited in their osteoclastogenesis, they were co-treated with GM-CSF (0.1 or 1 ng/ml) in addition to RANKL + M-CSF. Certainly, GM-CSF inhibited monocyte-derived osteoclast differentiation completely (Fig. 4B). Interestingly or as expected, the osteoclast differentiation of GM-OP and TNF-OP was not inhibited and they formed TRAP positive MGCs. Alternatively, additional GM-CSF treatment significantly increased the number of TRAP positive MGCs compared with no GM-CSF treatment (Fig. 4C).

Through comparison of TNF-OP derived OC and GM-OP derived OC, TNF α treatment always increased the number of TRAP positive MGCs in spite of additional GM-CSF.

Surprisingly, additional GM-CSF treatment suppressed their resorption ability, not only in monocyte-derived osteoclasts but also in GM-OP and TNF-OP derived osteoclasts (Fig. 4D). It was revealed that both GM-OP and




Fig. 3. Both osteoclasts expressed actin-ring and CATK. Representative figures of permeabilized GM-OP-derived osteoclasts (left) and TNF-OP-derived osteoclasts (right) were shown in rhodamine-labeled phalloidin (red) (upper) and in CATK staining (green)/DAPI (blue) (lower) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.).




Fig. 4. Their osteoclast differentiation was not inhibited by GM-CSF. (A) Representative TRAP stain figures of (a) GM-OP-derived, (b) TNF-OP-derived or (c) monocyte-derived osteoclasts were shown: Bar = 100 μ m. (d) Magnified figures of TNF-OP-derived osteoclasts: Bar = 50 μ m. (B) Representative TRAP stain figures of monocyte-derived (top), GM-OP-derived (middle) or TNF-OP-derived (bottom) osteoclasts were shown, co-treated with GM-CSF 0 ng/ml (left), 0.1 ng/ml (center), and 1 ng/ml (right). (C) The number of TRAP-positive MGCs per field was counted. GM-CSF 0 ng/ml (left), 0.1 ng/ml (center), and 1 ng/ml (right). Results are expressed as means \pm SD ($^*p < 0.05$; GM-OP v.s. TNF-OP, $^{**}p < 0.05$, $^{***}p < 0.05$; 0 ng/ml GM-CSF v.s. 0.1 or 1 ng/ml GM-CSF). (D) The resorption area on carbonated calcium phosphate coated plate was calculated. GM-CSF 0 ng/ml (left), 0.1 ng/ml (center), and 1 ng/ml (right). Results are expressed as means \pm SD.

TNF-OP derived osteoclasts were not inhibited the differentiation, rather the resorption by GM-CSF.

Discussion

The osteoclasts have been considered as the sole bone resorbing cell, derived from monocyte/macrophage. Recently immature DC has demonstrated transdifferentiation into osteoclasts in vitro [27]. This has noticed us the unknown origin of osteoclast precursors except for monocyte/macrophage.

We have shown that monocyte-derived cells generated in GM-CSF (GM-OP) could be another lineage of osteoclast precursor cells that are distinguishable from cDC and monocyte/macrophage. They expressed CD11b, compatible with osteoclast precursors induced by TNF α in vivo [28].

These cells could differentiate into osteoclasts in the presence of RANKL and M-CSF. They possessed about 3–10 nuclei and expressed a characteristic actin ring and CATK. The resorption area of monocyte-derived osteoclasts was considerably larger than that of GM-OP derived

osteoclasts, though the numbers of TRAP positive MGCs were almost the same. This inconsistency was probably because of the larger size of monocyte-derived osteoclasts. Furthermore by TNF α treatment, GM-OP became TNF-OP and then acquired much stronger osteoclastic activity. It was noteworthy that the early action of TNF α not only increased the number of osteoclast precursors, but also activated the resorption ability at the late stage.

As GM-CSF is detected abundantly in RA synovial fluid and scarcely detected in non-inflammatory synovial fluid, these osteoclast precursors seem to appear only in inflammatory arthritis [19]. In fact, we confirmed that GM-CSF was rarely detected in osteoarthritis synovial fluid and elevated in RA by about thirty times (data not shown). This elevation was equal to TNF α . In inflammatory arthritis such as RA, TNF α is always focused by the therapeutic effectiveness, but attention to GM-CSF should also be paid due to its elevation and specificity in the inflammatory environment [29]. Moreover, GM-CSF has been detected in the erosive inflammatory reaction around orthopedic implants or in the osteolytic bone metastasis by malignant tumor [30,31]. GM-CSF must have a pivotal function in bone destruction accompanied with inflammation.

GM-CSF, however, has an inhibitory effect against osteoclastogenesis [12,13]. During response to inflammation, GM-CSF may be released so as to inhibit severe bone destruction. Though it can surely block severe bone destruction, a marked number of neutrophils and macrophages will accumulate in the site, resulting in severe inflammation. GM-CSF can block osteoclastogenesis, but cannot block inflammation and arthritis. Taken that bone destruction always sympathizes with inflammation in arthritis, this incidence is impossible.

Even under such a strong inhibitory effect, GM-OP and TNF-OP could differentiate into osteoclasts. GM-OP and TNF-OP may elucidate this contradiction. This implies the existence of some different differentiation pathway and crosstalk from monocyte/macrophage-derived osteoclastogenesis.

In monocyte/macrophage-derived osteoclastogenesis, M-CSF is known for its crucial role of the survival and proliferation in osteoclast precursors [3]. RANKL is essential for osteoclast development and the determinant of the level of bone resorption [4]. TNF α increases osteoclast precursors, stimulates RANKL and M-CSF production by stromal cells and induces osteoclastogenesis in the presence of M-CSF [5].

On the other hand, in this 'inflammatory' osteoclastogenesis TNF α increased osteoclast precursors and endowed osteoclast precursors (GM-OP) with strong osteoclastic activity in spite of GM-CSF interference. GM-CSF gave rise to osteoclast precursors and promoted the proliferation of osteoclast precursors. Taking this into account, GM-CSF was almost substituted for M-CSF. This is contradictory to osteoclastogenesis at steady state [32]. Therefore, considering osteoclastogene-

sis, we should distinguish between inflammatory from non-inflammatory states.

In this current study GM-OP and TNF-OP proved to be able to survive as osteoclast precursors without the resorption ability. In other words, they were thought to wait for other signal than RANKL or M-CSF and be ready for resorbing and destroying the bone. Moreover, only RANKL could give the resorption ability to these precursors (data not shown). This suggested M-CSF-independent bone resorption might occur in inflammation. We could not find another inflammatory signal that gave resorption ability. IL-1, which promotes multinucleation of osteoclast precursors and enhances the capacity of the mature osteoclasts to resorb bone, or an unknown ligand, which stimulates DAPI2, may be a good candidate [10,33]. Further study is necessary.

Therefore, when we think about 'inflammatory' osteoclastogenesis, we never neglect to consider GM-CSF in addition to TNF α . In a RA cytokine environment, it should be called not only TNF immunity but also GM-CSF immunity. The importance of GM-CSF in inflammation and autoimmunity has been often pointed out [23]. Some RA patients whom anti-TNF therapy did not work might get better by anti-GM-CSF therapy. Many reports that indicated anti-GM-CSF therapy effectiveness on inflammatory arthritis support this notion [24,25].

In conclusion, our study revealed that myeloid cells induced by GM-CSF could differentiate into osteoclasts and acquire stronger osteoclastic activity in the presence of TNF α . Considering GM-CSF is detectable only at the inflammation site and their osteoclast differentiation is not inhibited by GM-CSF, these osteoclast precursor cells are specialized for inflammatory arthritis. There is another lineage distinguishable from cDC and monocyte/macrophage. We are the first to suggest the existence of 'inflammatory' osteoclastogenesis and the mechanism involved. Clarification of the mechanism of 'inflammatory' osteoclastogenesis will undoubtedly lead us to a new therapy for inflammatory arthritis, such as RA.

Acknowledgement

This work was supported in part by Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology (17390417).

References

- [1] S.L. Teitelbaum, Bone resorption by osteoclasts, *Science* 289 (2000) 1504–1508.
- [2] T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, T.J. Martin, Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor ligand families, *Endocr. Rev.* 20 (1999) 345–357.
- [3] S. Tanaka, N. Takahashi, N. Udagawa, T. Tamura, T. Akatsu, E.R. Stanley, T. Kurokawa, T. Suda, Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors, *J. Clin. Invest.* 91 (1993) 257–263.

- [4] L.E. Theill, W.J. Boyle, J.M. Penninger, RANKL and RANK: T cells, bone loss, and mammalian evolution, *Annu. Rev. Immunol.* 20 (2002) 795–823.
- [5] J. Lam, S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, S.L. Teitelbaum, TNF- α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand, *J. Clin. Invest.* 106 (2000) 1481–1488.
- [6] H. Takayanagi, Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems, *Nat. Rev. Immunol.* 7 (2007) 292–304.
- [7] G.S. Firestein, Evolving concepts of rheumatoid arthritis, *Nature* 423 (2003) 356–361.
- [8] J.E. Mulder, N.S. Kolatkar, M.S. LeBoff, Existing and emerging therapies for osteoporosis, *Nat. Clin. Pract. Endocrinol. Metab.* 12 (2006) 670–680.
- [9] I.B. McInnes, G. Schett, Cytokines in the pathogenesis of rheumatoid arthritis, *Nat. Rev. Immunol.* 7 (2007) 429–442.
- [10] L.C. Hofbauer, D.L. Lacey, C.R. Dunstan, T.C. Spelsberg, B.L. Riggs, S. Khosla, Interleukin-1 β and tumor necrosis factor- α , but not interleukin-6, stimulates osteoprotegerin ligand gene expression in human osteoblastic cells, *Bone* 25 (1999) 255–259.
- [11] S. Wei, H. Kitaura, P. Zhou, F.P. Ross, S.T. Teitelbaum, IL-1 mediates TNF-induced osteoclastogenesis, *J. Clin. Invest.* 115 (2005) 282–290.
- [12] T. Miyamoto, O. Ohneda, F. Arai, K. Iwamoto, S. Okada, K. Takagi, D.M. Anderson, T. Suda, Bifurcation of osteoclasts and dendritic cells from common progenitors, *Blood* 98 (2001) 2544–2554.
- [13] S.D. Yogesha, S.M. Khapli, M.R. Wani, Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)- α induced osteoclast differentiation by down-regulation of expression of TNF Receptors 1 and 2, *J. Biol. Chem.* 280 (2005) 11759–11769.
- [14] H. Takayanagi, K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokouchi, H. Oda, K. Tanaka, K. Nakamura, T. Taniguchi, T cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN- γ , *Nature* 408 (2000) 600–605.
- [15] N. Udagawa, N.J. Horwood, J. Elliott, A. Mackay, J. Owens, H. Okamura, M. Kurimoto, T.J. Chambers, T.J. Martin, M.T. Gillespie, Interleukin-18 (interferon- γ -inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon- γ to inhibit osteoclast formation, *J. Exp. Med.* 185 (1997) 1005–1012.
- [16] S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin, T. Suda, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, *J. Clin. Invest.* 109 (1999) 1345–1352.
- [17] K. Sato, A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, D.J. Cua, H. Takayanagi, Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction, *J. Exp. Med.* 203 (2006) 2673–2682.
- [18] J.A. Gracie, R.J. Forshey, W.L. Chan, A. Gilmour, B.P. Leung, M.R. Greer, K. Kennedy, R. Carter, X.Q. Wei, D. Xu, M. Field, A. Foulis, F.Y. Liew, I.B. McInnes, A proinflammatory role for IL-18 in rheumatoid arthritis, *J. Clin. Invest.* 104 (1999) 1393–1401.
- [19] D.J. Williamson, C.G. Begley, M.A. Vadas, D. Metcalf, The detection and initial characterization of colony-stimulating factors in synovial fluid, *Clin. Exp. Immunol.* 72 (1988) 67–73.
- [20] A.W. Burgess, D. Metcalf, The nature of and action of granulocyte-macrophage colony stimulating factors, *Blood* 56 (1980) 947–958.
- [21] J. Cebon, J.E. Layton, D. Maher, G. Morstyn, Endogenous haemopoietic growth factors in neutropenia and infection, *Br. J. Haematol.* 86 (1994) 265–274.
- [22] E. Stanley, G.J. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J.A. Gall, D.W. Maher, J. Cebon, V. Sinickas, A.R. Dunn, Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of haematopoiesis but develop a characteristic pulmonary pathology, *Proc. Natl. Acad. Sci. USA* 91 (1994) 5592–5596.
- [23] J.A. Hamilton, GM-CSF in inflammation and autoimmunity, *Trends Immunol.* 23 (2002) 403–408.
- [24] A.D. Cook, E.L. Braine, I.K. Campbell, M.J. Rich, J.A. Hamilton, Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease, *Arthritis Res.* 3 (2001) 293–298.
- [25] Y.H. Yang, J.A. Hamilton, Dependence of interleukin-1 induced arthritis on granulocyte-macrophage colony-stimulating factor, *Arthritis Rheum.* 44 (2001) 111–119.
- [26] J. Cornish, M.T. Gillespie, K.E. Callon, N.J. Horwood, J.M. Moseley, I.R. Reid, Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells, *Endocrinology* 144 (2003) 1194–1201.
- [27] A. Rivollier, M. Mazzonara, J. Tebib, M. Piperno, T. Aitsisselmi, C. Rbourdin-Combe, P. Jurdic, C. Servet-Delprat, Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment, *Blood* 104 (2004) 4029–4037.
- [28] P. Li, E.M. Schwarz, R.J. O'Keefe, L. Ma, R.J. Looney, C.T. Ritchlin, B.F. Boyce, L. Xing, Systemic tumor necrosis factor α mediates an increase in peripheral CD11b high osteoclast precursors in tumor necrosis factor transgenic mice, *Arthritis Rheum.* 50 (2004) 265–276.
- [29] M. Feldmann, R.N. Maini, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? *Annu. Rev. Immunol.* 19 (2001) 163–196.
- [30] N. Al-Saffar, H.A. Khwaja, Y. Kadoya, P.A. Revell, Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants, *Am. J. Clin. Pathol.* 105 (1996) 628–639.
- [31] B.K. Park, H. Zhang, Q. Zeng, J. Dai, E.T. Keller, T. Giordano, K. Gu, V. Shah, L. Pei, R.J. Zarbo, L. McCauley, S. Shi, S. Chen, C.Y. Wang, NF- κ B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF, *Nat. Med.* 13 (2007) 62–69.
- [32] J.M. Hodge, M.A. Kirkland, G.C. Nicholson, GM-CSF cannot substitute for M-CSF in human osteoclastogenesis, *Biochem. Biophys. Res. Commun.* 321 (2004) 7–12.
- [33] T. Koga, M. Inui, K. Inoue, S. Kim, A. Suematsu, E. Kobayashi, T. Iwata, H. Ohnishi, T. Matozaki, T. Kodama, T. Taniguchi, H. Takayanagi, T. Takai, Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis, *Nature* 428 (2004) 758–763.

Circulating Bone Marrow-Derived Osteoblast Progenitor Cells Are Recruited to the Bone-Forming Site by the CXCR4/Stromal Cell-Derived Factor-1 Pathway

SATORU OTSURI,^{a,b} KATSUTO TAMAI,^a TAKEHIKO YAMAZAKI,^a HIDEKI YOSHIKAWA,^b YASUFUMI KANEDA^a

^aDivision of Gene Therapy Science and ^bDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Key Words. Bone marrow cells • Chemokine receptor CXCR4 • Mobilization kinetics • Osteoblast • Peripheral blood
Stromal derived factor-1 • Stem/progenitor cell • Tissue regeneration

ABSTRACT

Previous studies demonstrated the existence of osteoblastic cells in circulating blood. Recently, we reported that osteoblast progenitor cells (OPCs) in circulation originated from bone marrow and contributed to the formation of ectopic bone induced by implantation of a bone morphogenetic protein (BMP)-2-containing collagen pellet in mouse muscular tissue. However, the character of circulating bone marrow-derived osteoblast progenitor cells (MOPCs) and the precise mechanisms involving the circulating MOPCs in the osteogenic processes, such as signals that recruit the circulating MOPCs to the osseous tissues, have been obscure. In this report, we demonstrated for the first time that the MOPCs were mobilized from intact bones to transiently occupy approximately 80% of the mononuclear cell population in the circulating blood by BMP-2-

pellet implantation. The mobilized MOPCs in the circulation did not express the hematopoietic marker CD45 on their surface, but they expressed CD44 and CXCR4, receptors of osteopontin and stromal cell-derived factor-1 (SDF-1), respectively. The MOPCs isolated from the mouse peripheral blood showed the ability to be osteoblasts *in vitro* and *in vivo*. Furthermore, the MOPCs in the circulation efficiently migrated to the region of bone formation by chemoattraction of SDF-1 expressed in vascular endothelial cells and the *de novo* osteoblasts of the region. These data may provide a novel insight into the mechanism of bone formation involving MOPCs in circulating blood, as well as perspective on the use of circulating MOPCs to accelerate bone regeneration in the future. *STEM CELLS* 2008;26:223–234

Disclosure of potential conflicts of interest is found at the end of this article.

INTRODUCTION

Bone marrow contains hematopoietic stem cells and mesenchymal stem/progenitor cells (MPCs) that can differentiate into various mesenchymal tissues, such as bone, cartilage, fat, and muscle [1–3]. These cells are also found in various mesenchymal tissues [4], although the relationship between the marrow mesenchymal stem/progenitor cells (MMPCs) and extramarrow MPCs has not been fully understood. Marrow MPCs have been shown to engraft not only in bone marrow but also in multiple mesenchymal tissues after systemic infusion [3, 5], suggesting that circulating blood might be a natural route for MMPC migration to the mesenchymal tissues *in vivo*.

Previous studies have shown the existence of osteoblast-lineage cells in the circulating blood of various mammals, including humans [6–8]. The circulating osteoblast-lineage cells were shown to form bone in culture and in transplanted animals [6]. Studies have also reported more circulating osteoblast-lineage cells during the adolescent growth spurt than in adulthood [6]. However, the origin and the functional role of those osteoblastic cells in human circulation are unclear.

Bone morphogenetic protein (BMP)-2 and other members of the BMP family are well-known inducers of bone formation *in vitro* and *in vivo* [9]. In the process of a fracture healing, BMP stimulation recruits MPCs to the fracture lesion and induces their differentiation into osteoblasts. An experimental model has also indicated that BMP-2 stimulation is essential for ectopic bone formation when BMP-2 is transplanted in the back muscles of mice [10]. Recently, we reported that marrow-derived osteoblast progenitor cells (MOPCs) in circulating blood participated in BMP-2-induced ectopic bone formation [11]. If circulating MOPCs play a major role in bone regeneration *in vivo*, efficient recruitment of MOPCs from bone marrow to the lesion seems to be critical to obtain mature and sufficient regeneration. However, the character of circulating MOPCs and precise mechanisms involving the MOPCs in the osteogenic processes, such as signals that recruit circulating MOPCs to the osseous tissues, have been obscure.

In this study, we characterized MOPCs in the circulating blood without expansion in culture and showed that MOPCs were mobilized in the circulation after stimulation with tissue injury, migrated to damaged tissues by chemoattraction of stromal cell-derived factor-1 (SDF-1), and provided a significant number of mature osteoblasts with BMP-2 stimulation during bone formation. We believe these findings provide novel insights into bone regeneration involving circulating MOPCs.

Correspondence: Katsuto Tamai, M.D., Ph.D., Division of Gene Therapy Science, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. Telephone: 81-6-6879-3901; Fax: 81-6-6879-3909; e-mail: tamai@gts.med.osaka-u.ac.jp Received July 1, 2007; accepted for publication September 28, 2007; first published online in *STEM CELLS EXPRESS* October 11, 2007. ©AlphaMed Press 1066-5099/2007/\$30.00/0 doi: 10.1634/stemcells.2007-0515

STEM CELLS 2008;26:223–234 www.StemCells.com

MATERIALS AND METHODS

Bone Marrow Transplantation

Under sterile conditions, bone marrow cells were isolated from 8- to 10-week-old male C57BL/6 transgenic mice that ubiquitously expressed enhanced green fluorescent protein (GFP) [12]. Eight- to 10-week-old female C57BL/6 mice were lethally irradiated with 10 Gy. For total bone marrow transplantation (BMT), each irradiated recipient received 5×10^8 bone marrow cells from GFP transgenic mice. For CD45/GFP double-positive BMT, the CD45-positive bone marrow cells of GFP transgenic mice were sorted using the magnetic cell sorting (MACS) system (Miltenyi Biotec, Bergisch Gladbach, Germany, <http://www.miltenyibiotec.com>). Each irradiated recipient received 4.5×10^6 CD45-positive marrow cells of GFP transgenic mice in combination with 0.5×10^6 CD45-negative marrow cells of wild-type mice. All BMT mice were used at least 6 weeks after BMT. All animals were handled according to approved protocols and the guidelines of the Animal Committee of Osaka University.

Parabiotic Mouse Model

The parabiotic mouse model was generated as previously described [13]. A total BMT mouse and a wild-type mouse (C57BL/6) were sutured from the olecranon to the knee joint on the corresponding lateral aspects.

Preparation and Implantation of BMP-2-Containing Collagen Pellets

Recombinant human BMP-2 was provided by Astellas Pharma Inc. (Tokyo, <http://www.astellas.com>). The BMP-2 was suspended in buffer solution (5 mmol/l glutamic acid, 2.5% glycine, 0.5% sucrose, and 0.01% Tween 80, pH 4.5) at a concentration of $1 \mu\text{g}/\mu\text{l}$. Next, $3 \mu\text{l}$ ($3 \mu\text{g}$ of BMP-2) of the BMP-2 solution was diluted in $22 \mu\text{l}$ of phosphate-buffered saline (PBS) and blotted into a porous collagen disc (6 mm diameter, 1 mm thickness), freeze-dried, and stored at -20°C . All procedures were carried out under sterile conditions. BMP-2-containing or control PBS-containing collagen pellets were implanted on the backs of BMT mice, parabiotic mice, C57BL/6 mice, or nude mice. Three weeks later, fluorescent photos of ectopic bones were taken using a digital microscope (Multi-viewer system VB-S20; Keyence, Osaka, Japan, <http://www.keyence.com>).

Immunohistochemistry and Analysis

The ectopic bones were removed and fixed with 4% paraformaldehyde at 4°C for 48 hours. After soft x-ray photos were taken, bones were decalcified with EDTA solution at 4°C for 6 days. The EDTA solution was changed every other day. After decalcification, the pellets were equilibrated in PBS containing 15% sucrose for 12 hours and then in PBS containing 30% sucrose for 12 hours, embedded in Tissue-Tek OCT Compound (Sakura Finetek, Tokyo, <http://www.sakurau.com>), frozen on dry ice, and stored at -20°C .

For immunofluorescence staining, 6- μm -thick sections were cut with a cryostat (Leica Microsystems AG, Wetzlar, Germany, <http://www.leica.com>). After washing, the sections were treated with 0.1% trypsin (Difco Laboratories, Detroit, MI, <http://www.bd.com/ds>) in PBS for 30 minutes at 37°C to activate antigens. Then, those sections were blocked with normal goat serum for 1 hour before incubation with polyclonal anti-mouse osteocalcin antibody (1:250; Takara Bio, Shiga, Japan, <http://www.takara-bio.com>) or polyclonal anti-mouse SDF-1a antibody (1:250; eBioscience Inc., San Diego, <http://www.ebioscience.com>). Subsequently, sections were stained with Alexa Fluor 546 goat anti-rabbit IgG secondary antibody (Molecular Probes, Eugene, OR, <http://probes.invitrogen.com>) for 2 hours. Then, sections were stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 minutes at room temperature and mounted with the antifade solution Vectashield (Vector Laboratories, Burlingame, CA, <http://www.vectorlabs.com>).

For staining endothelial progenitor cells and tissues around the pellets, the pellets were removed daily until day 7 after implantation. After removal, pellets were embedded in Tissue-Tek OCT Compound and frozen on dry ice. Six-micrometer-thick sections were blocked with normal goat serum for 1 hour before incubation with monoclonal anti-mouse CD31 antibody (1:250; BD Pharmingen, San Jose, CA, http://www.bdbiosciences.com/index_us.shtml), monoclonal anti-mouse CD34 antibody (1:100; BD Pharmingen), monoclonal anti-smooth-muscle actin antibody (1:250; Sigma-Aldrich, St. Louis, <http://www.sigmaaldrich.com>), or polyclonal anti-mouse SDF-1a antibody (1:250; eBioscience). Subsequently, sections were stained with Alexa Fluor 546 goat anti-rat IgG secondary antibody, Alexa Fluor 488 anti-rat IgG secondary antibody, or Alexa Fluor 488 anti-mouse IgG secondary antibody (Molecular Probes) with M.O.M. Kit (Vector Laboratories) for 2 hours. The sections were mounted with antifade solution Vectashield after 10 minutes of DAPI staining. All pictures were taken with a confocal laser microscope, model Radiance 2100 using LaserSharp 2000 software (Bio-Rad Japan, Tokyo, <http://www.bio-rad.com>). To assess the frequency of MOPCs for osteoblast differentiation, we counted the number of GFP-positive cells in the osteocalcin-positive osteoblasts lining the trabecular bone. The ratio was quantitatively calculated in at least five low-power visual fields.

Peripheral Blood Mononuclear Cell Isolation

Peripheral blood was taken from the heart with a 24-gauge needle and 1-ml syringe containing heparin and enriched for low-density mononuclear cells by Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden, <http://www.amersham.com>) centrifugation. Red blood cells were removed by resuspending in 0.125% Tris-NH₄Cl buffer and sieving through a nylon mesh. Isolated peripheral blood mononuclear cells (PBMCs) from BMP-2 pellet-implanted mice were reacted with anti-mouse CD45 microbeads (Miltenyi Biotec), and the CD45-negative cells dominantly containing MOPCs were sorted using the Midi-MACS system (Miltenyi Biotec) according to the manufacturer's protocol.

In Vitro Differentiation

For induction of osteoblast differentiation in culture, MACS-sorted CD45-negative PBMCs from BMP-2-implanted GFP transgenic mice were plated on a 24-well plate. The sorted cells were then inoculated in basal medium consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml streptomycin/penicillin, and 50% conditioned culture medium (DMEM with 10% FCS) of mouse bone marrow mesenchymal cells as a growth factor supplement (S. Otsuru and K. Tamai, unpublished data). To induce osteoblast differentiation, 300 ng/ml BMP-2 was added to the culture medium for 3 weeks. In some experiments, the sorted CD45-negative PBMCs were cultured in the osteogenic medium consisting of Iscove's modified Dulbecco's medium supplemented with 0.1 μM dexamethasone (Nacalai Tesque Inc., Kyoto, Japan, <http://www.nacalai.co.jp/en>), 10 mM β -glycerol phosphate (Sigma-Aldrich), and 0.05 mM ascorbic acid 2-phosphate (Sigma-Aldrich) for 3–4 weeks.

Alizarin Red S Staining

To observe calcium deposition, cells were fixed with 4% paraformaldehyde and stained with 2% alizarin red S (Nacalai Tesque) solution in water for 10 minutes. Excess stain was removed by several washes with distilled water.

Alkaline Phosphatase Assay

Alkaline phosphatase (ALP) activity was assessed as previously described [14]. Cell lysates were centrifuged, and supernatants were used for the enzyme assay. Alkaline phosphatase activity was measured according to the methods of Kind-King, using a test kit (Wako Chemical, Osaka, Japan, <http://www.wako-chem.com.jp/english>).

with phenylphosphate as a substrate. Enzyme activity was expressed in King-Armstrong units, normalized to protein concentration.

In Vivo Bone Forming Assay

Fully open interconnected porous calcium hydroxyapatite ceramics were synthesized by adopting a "foam-gel" technique from a slurry of hydroxyapatite (60% wt/wt) with a cross-linking substrate (polyethyleneimine, 40% wt/wt) as previously reported [15]. Blocks of the ceramics were cut and shaped into 5-mm-diameter disks that were 2 mm thick. Cell culturing in the pores of the ceramics was performed as previously reported [16, 17]. The ceramic disk was soaked in 200 μ l of CD45-negative cultured PBMC suspension from GFP-transgenic mice in normal medium (10^6 cells per milliliter). After overnight incubation in a 96-well plate, normal medium was changed to osteogenic medium. The medium was renewed three times a week, and the cultures were maintained for 2 weeks. After a wash with PBS, the disks were implanted under the muscular fascia in the backs of nude mice. Disks without cells were also implanted as controls. Eight weeks later, the disks were harvested and fixed in 4% paraformaldehyde. After decalcification with K-CX (Falma Co., Osaka, Japan; <http://www.falma.co.jp>), the disks were embedded in paraffin, and the sections were stained with hematoxylin and eosin.

For immunofluorescence staining, the sections were treated with 0.1% trypsin (Difco Laboratories) in PBS for 30 minutes at 37°C to activate antigens. Next, those sections were blocked with normal goat serum for 1 hour before incubation with polyclonal anti-GFP antibody (1:250; MBL International Corp., Nagoya, Japan; <http://www.mblintl.com>). Subsequently, sections were stained with Alexa Fluor 488 goat anti-rabbit IgG secondary antibody (Molecular Probes) for 2 hours. Sections were then stained with DAPI for 10 minutes at room temperature and mounted with the antifade solution Vectashield (Vector Laboratories).

RNA Extraction and Reverse Transcription-Polymerase Chain Reaction

Total RNA was prepared with an RNeasy Kit (Qiagen, Tokyo, <http://www1.qiagen.com>) according to the manufacturer's protocol. Reverse transcription was performed by conventional protocols with Superscript reverse transcriptase (Invitrogen, Carlsbad, CA; <http://www.invitrogen.com>), and polymerase chain reaction (PCR) amplification was performed using the following primer sets: Cbfa1 (NM_009820, 289 base pairs [bp]), 5'-CCG-CACGACAACCGCACCAT-3' (forward) and 5'-CGCTCCGGC-CCACAAATCTC-3' (reverse); osteopontin (NM_009263, 437 bp), 5'-TCACCATTCGGATGAGTCTG-3' (forward) and 5'-ACTTGTGGCTCTGATGTTCC-3' (reverse); ALP (NM_007431, 180 bp), 5'-CGCCAGAGTACGCTCCCGCC-3' (forward) and 5'-TG-TACCCTGAGATTCGT-3' (reverse); osteocalcin (X04142, 350 bp), 5'-CTGACCTCACAGATCCCAAG-3' (forward) and 5'-GGAGCTGCTGTGACATCC-3' (reverse); and SDF-1 (NM_021704, 538 bp), 5'-ACGCCAAGGTGGTCCCGCTGG-3' (forward) and 5'-GTTAGGTAATACAATTCCTTAGA-3' (reverse).

Flow Cytometry

Isolated PBMCs were suspended in 100 μ l of PBS containing fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD45; phycoerythrin (PE)-conjugated anti-mouse CD11b, CD31, CD34, CD44, Fik-1, and Sca-1 (BD Pharmingen); and biotin-conjugated anti-mouse Gr-1 and CXCR4 (BD Pharmingen). Cells were then incubated for 30 minutes at 4°C in the dark. Subsequently, cells were stained with Streptavidin PE or Streptavidin PerCP (BD Pharmingen) or anti-rat IgG secondary antibody or anti-goat IgG secondary antibody (Molecular Probes) for 30 minutes at 4°C in the dark.

For the time-course analysis of the CD45-negative population in PBMCs, BMP-2 pellets were implanted on the backs of 8- to 10-week-old female C57BL/6 mice daily, one mouse per day, for 7 days. At day 7, blood samples were taken, and hemolyzed PBMCs were harvested. The harvested PBMCs were reacted with FITC-conjugated anti-mouse CD45. Flow cytometry analysis was per-

formed with a FACScan instrument using CellQuest software (Becton, Dickinson and Company, San Diego, <http://www.bd.com>).

In Vitro Migration Assay

After different concentrations of SDF-1 α (R&D Systems Inc., Minneapolis, <http://www.rndsystems.com>) were added to the lower chamber, the 5×10^5 isolated CD45-negative PBMCs from BMP-2 pellet-implanted mice in 100 μ l of DMEM without growth factors were applied to the upper chamber of the membrane of the 96-well cell migration kit (Chemicon, Temecula, CA; <http://www.chemicon.com>). Some cells were pretreated with a CXCR4-blocking antibody (2B11; BD Pharmingen). After 4 hours of incubation at 37°C, the migratory cells on the bottom of the insert membrane were dissociated from the membrane by incubation with cell detachment buffer. These cells were stained with CyQuant GR dye (Molecular Probes, Eugene, OR; <http://probes.invitrogen.com>), and the fluorescence was measured with a fluorescence plate reader.

In Vivo Migration Assay

For the transplantation experiment, nude mice implanted with BMP-2-containing collagen pellets were injected via a tail vein with sorted CD45-negative PBMCs with or without CXCR4-blocking antibody (2B11; BD Pharmingen) pretreatment from the GFP-transgenic BMP-2-implanted mice for 7 days.

Real-Time PCR

Primers and probes for hypoxia inducible factor-1 (HIF-1), SDF-1, and glyceraldehyde-3-phosphate dehydrogenase were purchased from Applied Biosystems (Foster City, CA; <http://www.appliedbiosystems.com>). Real-time PCR was carried out and measured by the ABI Prism 7900HT Sequence Detection System using SDS 2.2 software (Applied Biosystems).

Statistical Analysis

All experiments were repeated four to seven times. Statistical analyses were performed with the unpaired *t* test or the paired Student *t* test. *p* values <0.05 were considered statistically significant.

RESULTS

Bone Marrow-Derived Osteoblast Progenitor Cells in Circulation Contribute to BMP-2-Induced Ectopic Bone Formation

We have already reported that osteoblast progenitor cells (OPCs) were recruited from bone marrow to the circulating blood and contributed to the BMP-2-induced ectopic bone formation [11]. To obtain more direct evidence that circulating MOPCs were recruited to the region of the BMP-2 pellet to generate ectopic bone, we established a mouse model with parabiotic pairings that shared a circulatory system between a wild-type mouse and a GFP-BMT mouse (Fig. 1A) [13]. In our parabiotic mouse model, a wild-type mouse was surgically connected with a GFP-BMT mouse whose bone marrow had been replaced by GFP-transgenic bone marrow cells. The wild-type mouse can receive bone marrow-derived GFP-positive circulating cells from the GFP-BMT mouse after they develop shared circulation in a few weeks. We implanted a BMP-2 pellet into the wild-type mouse of the parabiotic pairings (Fig. 1A). Three weeks after transplantation, GFP fluorescence was detected at the region where the ectopic bone had formed (Fig. 1B). Histologic analysis revealed that 24.5% \pm 3.1% of the osteoblasts that aligned on the regenerating bone and expressed osteocalcin (OC) were GFP-positive cells that originated from the bone marrow of the GFP-BMT mouse (Fig. 1C; supplemental online Fig. 1).